{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:18:08Z","timestamp":1776107888997,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008048","name":"Nanjing University","doi-asserted-by":"publisher","award":["2021-LCYJ-PY-09"],"award-info":[{"award-number":["2021-LCYJ-PY-09"]}],"id":[{"id":"10.13039\/501100008048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470517"],"award-info":[{"award-number":["82470517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070496"],"award-info":[{"award-number":["82070496"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.avsg.2026.01.043","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:25:03Z","timestamp":1771374303000},"page":"391-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A Real-World Pharmacovigilance Study of Cilostazol Based on the Food and Drug Administration Adverse Event Reporting System: A Cross-Sectional Disproportionality Analysis"],"prefix":"10.1016","volume":"127","author":[{"given":"Hong-Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Long","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2026.01.043_bib1","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"Brown","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.avsg.2026.01.043_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosis.2005.11.027","article-title":"Intermittent claudication: an overview","volume":"187","author":"Meru","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.avsg.2026.01.043_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/bmj.39001.562813.DE","article-title":"Intermittent claudication","volume":"333","author":"Cassar","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2026.01.043_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.96.1.44","article-title":"Intermittent claudication. A risk profile from the Framingham Heart Study","volume":"96","author":"Murabito","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.01.043_bib5","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/01.CIR.91.5.1472","article-title":"Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study","volume":"91","author":"Hiatt","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.01.043_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1067\/mva.2001.112210","article-title":"Outcome events in patients with claudication: a 15-year study in 2777 patients","volume":"33","author":"Muluk","year":"2001","journal-title":"J Vasc Surg"},{"issue":"Suppl 3","key":"10.1016\/j.avsg.2026.01.043_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003495-199856003-00004","article-title":"[Evaluation of the impact of peripheral obliterative arteriopathy on quality of life]","volume":"56","author":"Marquis","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.avsg.2026.01.043_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.yasu.2023.04.009","article-title":"Current management of intermittent claudication","volume":"57","author":"Stonko","year":"2023","journal-title":"Adv Surg"},{"key":"10.1016\/j.avsg.2026.01.043_bib9","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1161\/01.CIR.0000128517.52533.DB","article-title":"Atherosclerotic Vascular Disease Conference: executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association","volume":"109","author":"Faxon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.01.043_bib10","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.2174\/092986710792065018","article-title":"Regulators of platelet cAMP levels: clinical and therapeutic implications","volume":"17","author":"No\u00e9","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.avsg.2026.01.043_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00002512-199914010-00005","article-title":"Cilostazol","volume":"14","author":"Sorkin","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.avsg.2026.01.043_bib12","first-page":"e686","article-title":"2016 AHA\/ACC Guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American college of Cardiology\/American Heart Association task force on clinical practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.01.043_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.44938","article-title":"Efficacy and safety of cilostazol in mild cognitive impairment: a randomized clinical trial","volume":"6","author":"Saito","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.avsg.2026.01.043_bib14","doi-asserted-by":"crossref","first-page":"28d","DOI":"10.1016\/S0002-9149(01)01719-2","article-title":"Analysis of the cilostazol safety database","volume":"87","author":"Pratt","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.avsg.2026.01.043_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12882-018-0854-0","article-title":"Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report","volume":"19","author":"Shima","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.avsg.2026.01.043_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.avsg.2026.01.043_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.avsg.2026.01.043_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.avsg.2026.01.043_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase(\u00ae)","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.avsg.2026.01.043_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"Guo","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.avsg.2026.01.043_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/ph14050425","article-title":"Signal detection of adverse drug reactions of cephalosporins using data from a national pharmacovigilance database","volume":"14","author":"Choi","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.avsg.2026.01.043_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.seizure.2023.07.003","article-title":"Real-world safety of lacosamide: a pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system","volume":"110","author":"Liu","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.avsg.2026.01.043_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2105-15-17","article-title":"Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection","volume":"15","author":"Xu","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.avsg.2026.01.043_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database","volume":"23","author":"Lindquist","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.avsg.2026.01.043_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.avsg.2026.01.043_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.avsg.2026.01.043_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.avsg.2026.01.043_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.avsg.2026.01.043_bib29","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209750","article-title":"Incident infarcts in patients with stroke and cerebral small vessel disease: frequency and relation to clinical outcomes","volume":"103","author":"Clancy","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.avsg.2026.01.043_bib30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.CIR.98.7.678","article-title":"Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial","volume":"98","author":"Dawson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.01.043_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-642-29423-5_9","article-title":"Targeting phosphodiesterases in anti-platelet therapy","volume":"210","author":"Rondina","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.avsg.2026.01.043_bib32","first-page":"Cd003748","article-title":"Cilostazol for intermittent claudication","volume":"2014","author":"Bedenis","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"10.1016\/j.avsg.2026.01.043_bib33","first-page":"S14","article-title":"The pharmacology of cilostazol","volume":"4","author":"Schr\u00f6r","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.avsg.2026.01.043_bib34","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1161\/STROKEAHA.121.035002","article-title":"Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities","volume":"52","author":"de Havenon","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.avsg.2026.01.043_bib35","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.avsg.2026.01.043_bib36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2023.1526","article-title":"Isosorbide mononitrate and cilostazol treatment in patients with symptomatic cerebral small vessel disease: the lacunar intervention Trial-2 (LACI-2) randomized clinical trial","volume":"80","author":"Wardlaw","year":"2023","journal-title":"JAMA Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.avsg.2026.01.043_bib37","first-page":"1","article-title":"Cilostazol research in Asia: can it be applied to European and American patients?","volume":"10","author":"Kim","year":"2015","journal-title":"Int J Stroke"},{"key":"10.1016\/j.avsg.2026.01.043_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2459\/JCM.0b013e3283439746","article-title":"Effects of cilostazol in the heart","volume":"12","author":"Kanlop","year":"2011","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.avsg.2026.01.043_bib39","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3390\/ijms25052593","article-title":"The role of cilostazol, a Phosphodiesterase-3 inhibitor, in the development of atherosclerosis and vascular biology: a review with meta-analysis","volume":"25","author":"Sohn","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.avsg.2026.01.043_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/23969873231219416","article-title":"European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke","volume":"9","author":"Wardlaw","year":"2024","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.avsg.2026.01.043_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fbioe.2020.00123","article-title":"Thrombogenic and inflammatory reactions to biomaterials in medical devices","volume":"8","author":"Labarrere","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.avsg.2026.01.043_bib42","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0142-9612(96)80004-4","article-title":"Proteins involved in the Vroman effect during exposure of human blood plasma to glass and polyethylene","volume":"17","author":"Turbill","year":"1996","journal-title":"Biomaterials"},{"issue":"Suppl 1","key":"10.1016\/j.avsg.2026.01.043_bib43","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.avsg.2026.01.043_bib44","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1253\/circj.71.608","article-title":"Dynamic intraventricular obstruction in acute myocardial infarction with administration of cilostazol","volume":"71","author":"Ozaki","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.avsg.2026.01.043_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520965807","article-title":"Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports","volume":"48","author":"Yuan","year":"2020","journal-title":"J Int Med Res"},{"issue":"6 Suppl","key":"10.1016\/j.avsg.2026.01.043_bib46","first-page":"III120","article-title":"Electrophysiological mechanisms involved in ventricular fibrillation","volume":"52","author":"Zipes","year":"1975","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2026.01.043_bib47","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/cvr\/cvaa246","article-title":"Two sides of the same coin: new insights into mechanisms of ventricular fibrillation","volume":"117","author":"Bezzerides","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.avsg.2026.01.043_bib48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.hrcr.2017.07.005","article-title":"Oral quinine sulfate for the treatment of electrical storm and prevention of recurrent shocks in Brugada syndrome after failed cilostazol therapy","volume":"3","author":"Shenthar","year":"2017","journal-title":"Heartrhythm Case Rep"},{"key":"10.1016\/j.avsg.2026.01.043_bib49","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.hrthm.2014.05.001","article-title":"Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes","volume":"11","author":"Shinohara","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.avsg.2026.01.043_bib50","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1046\/j.1540-8167.2002.00698.x","article-title":"Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome","volume":"13","author":"Tsuchiya","year":"2002","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.avsg.2026.01.043_bib51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.hrthm.2012.11.001","article-title":"Beneficial effects of cilostazol in a patient with recurrent ventricular fibrillation associated with early repolarization syndrome","volume":"10","author":"Iguchi","year":"2013","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.avsg.2026.01.043_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1161\/CIRCEP.113.000919","article-title":"Cellular mechanism underlying hypothermia-induced ventricular tachycardia\/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone","volume":"7","author":"Gurabi","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.avsg.2026.01.043_bib53","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1540-8167.2005.00290.x","article-title":"Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome","volume":"17","author":"Abud","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.avsg.2026.01.043_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116796","article-title":"Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke","volume":"413","author":"Aoki","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.avsg.2026.01.043_bib55","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/0735-1097(91)90508-7","article-title":"Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up","volume":"18","author":"Wang","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2026.01.043_bib56","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.3390\/jcm12186089","article-title":"Cardiovascular safety evaluation of febuxostat and allopurinol: findings from the FDA adverse event reporting System","volume":"12","author":"Bai","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.avsg.2026.01.043_bib57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1573403X15666181212125024","article-title":"Shock - Classification and pathophysiological principles of therapeutics","volume":"15","author":"Kislitsina","year":"2019","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.avsg.2026.01.043_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.37","article-title":"Disseminated intravascular coagulation","volume":"2","author":"Gando","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.avsg.2026.01.043_bib59","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2020007208","article-title":"Disseminated intravascular coagulation and its immune mechanisms","volume":"139","author":"Popescu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.avsg.2026.01.043_bib60","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.avsg.2026.01.043_bib61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1592\/phco.29.5.526","article-title":"Pharmacologic therapy for intermittent claudication","volume":"29","author":"Dobesh","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.avsg.2026.01.043_bib62","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/clpt.2008.98","article-title":"Genetic variation in drug transporters in ethnic populations","volume":"84","author":"Cropp","year":"2008","journal-title":"Clin Pharmacol Ther"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509626000889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509626000889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:47:01Z","timestamp":1776102421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509626000889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":62,"alternative-id":["S0890509626000889"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2026.01.043","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Real-World Pharmacovigilance Study of Cilostazol Based on the Food and Drug Administration Adverse Event Reporting System: A Cross-Sectional Disproportionality Analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2026.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}